Value of Cantrixil

Harvett, how much do you think a partner would be willing to pay for Cantrixil?

A search will show that the Cantrixil Phase 1 abstract has been accepted as a poster presentation at ESMO in September, but unfortunately it looks like the data was not good enough to warrant an oral presentation. Kazia will need to find a way to separate itself from a pack of thousands if it is to land a partnership deal at ESMO.

A prospective partner would know that Kazia is in effect a stressed seller, needing the funds to progress GDC-0084. Ironically, Kazia needs someone like itself (when it had the money) who would be willing to take Cantrixil through Phase II.

As a number of posters have said, it is a good thing that some prestigious institutions are using GDC-0084 in clinical trials. The downside is that these institutions own the data and will release it at a time of their choosing, probably at major conferences, which may be too late to boost the share price before a CR is necessary.

We are getting to a critical point. Kazia needs funds but prospective lenders will wonder how they could sell any shares issued as part of a PIPE. Data from Part B of the Cantrixil trial will take time to mature, and so Kazia may be dependant on GDC-0084 data, which will have to be good, and known before funds run out.

The share price remains in the doldrums because of uncertainty about finance, in my opinion. It would be a brave person who bought at these levels, when the likelihood is that the SP will drop when a funding deal is announced.

Let’s hope JG can pull a rabbit out of his hat.